0001552189 false 0001552189 2021-10-25 2021-10-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 25, 2021

 

PANACEA LIFE SCIENCES HOLDINGS, INC.

(Exact name of the registrant as specified in its charter)

 

Nevada   001-38190   27-1085858
(State or other jurisdiction of   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

5910 South University Blvd, C18-193

Greenwood Village, CO 80121

 

 

(Address of principal executive offices) (Zip code)

 

Registrant’s telephone number, including area code: 1-800-985-0515

 

Exactus, Inc.

 

 

(Former name or address if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

Name Change and Reverse Split

 

On October 25, 2021, Exactus, Inc. (the “Company”) filed with the Secretary of State of the State of Nevada a Certificate of Amendment to its Amended and Restated Articles of Incorporation to change the Company’s name to Panacea Life Sciences Holdings, Inc. and effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one-for-28 basis (collectively, the “Amendment”).

 

Designation of Preferred Stock

 

On October 25, 2021, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate”) of Series C-2 Convertible Preferred Stock (the “Series C-2”). The Series C-2 designates 100 shares for issuance, par value $0.0001 per share. Each share of Series C-2 is convertible into 2,050,000 shares of the Company’s common stock and is entitled to vote on all matters submitted to the Company’s stockholders on an as-converted basis. Other than the conversion and voting rights, there are no other preferences.

 

All 100 designated shares of Series C-2 were issued to Quintel-MC Incorporated (“Quintel”) in connection with the cancellation of 205,000,000 shares of the Company’s common stock that were held by Quintel. Leslie Buttorff, the Company’s Chief Executive Officer and director, is the sole owner, officer and director of Quintel.

 

The foregoing description of the Amendment and the Series C-2 does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment and the Certificate, which are filed as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits.

 

Exhibit
No.
  Description.
     
3.1   Certificate of Amendment to its Amended and Restated Articles of Incorporation
3.2   Certificate of Designation of Preferences, Rights and Limitations of Series C-2 Convertible Preferred Stock
104  

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf of the undersigned hereunto duly authorized.

 

  PANACEA LIFE SCIENCES HOLDINGS, INC.
     
 Date: October 29, 2021 By: /s/ Leslie Buttorff
  Name: Leslie Buttorff
  Title: Chief Executive Officer

 

 

 

 

Exhibit 3.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 3.2

 

CERTIFICATE OF DESIGNATION OF PREFERENCES,

RIGHTS AND LIMITATIONS

OF

SERIES C-2 CONVERTIBLE PREFERRED STOCK

 

The undersigned, Chief Executive Officer of Exactus, Inc., a Nevada corporation (the “Corporation), DOES HEREBY CERTIFY that the following resolutions were duly adopted by the Board of Directors of the Corporation by unanimous written consent on October 21, 2021;

 

WHEREAS, the Board of Directors is authorized within the limitations and restrictions stated in the Articles of Incorporation of the Corporation, as amended, to provide by resolution or resolutions for the issuance of 50,000,000 shares of Preferred Stock, par value $0.0001 per share, of the Corporation, in such series and with such designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions as the Corporation’s Board of Directors shall fix by resolution or resolutions providing for the issuance thereof duly adopted by the Board of Directors; and

 

WHEREAS, it is the desire of the Board of Directors, pursuant to its authority as aforesaid, to authorize and fix the terms of a series of Preferred Stock and the number of shares constituting such series; and

 

WHEREAS, all currency amounts set forth herein shall be stated in United States Dollars (USD).

 

NOW, THEREFORE, BE IT RESOLVED:

 

1. Designation and Authorized Shares. The Corporation shall be authorized to issue 100 shares of Series C-2 Convertible Preferred Stock, par value $0.0001 per share (the “Series C-2 Preferred Stock”).

 

2. Voting. Except as otherwise expressly required by law, each holder of Series C-2 Preferred Stock shall be entitled to vote on all matters submitted to shareholders of the Corporation and shall be entitled to the number of votes for each share of Series C-2 Preferred Stock owned at the record date for the determination of shareholders entitled to vote on such matter or, if no such record date is established, at the date such vote is taken or any written consent of shareholders is solicited, equal to the number of shares of Common Stock (as defined below) that such shares of Series C-2 Preferred Stock are convertible into at such time. Except as otherwise required by law, the holders of shares of Series C-2 Preferred Stock shall vote together with the holders of Common Stock on all matters and shall not vote as a separate class.

 

3. Conversion.

 

3.1 Conversion Right. Each holder of Series C-2 Preferred Stock may, from time to time, convert any or all of such holder’s shares of Series C-2 Preferred Stock into fully paid and non-assessable shares of Common Stock in an amount equal to 2,050,000 shares of the Corporation’s common stock, par value $0.0001 per share (the “Common Stock”) for each one share of Series C-2 Preferred Stock surrendered (the “Conversion Rate”). The Corporation shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, the Corporation shall round such fraction of a share of Common Stock up to the nearest whole share.

 

 

 

 

3.2 Conversion Procedure. In order to exercise the conversion privilege under this Section 3, the holder of any shares of Series C-2 Preferred Stock to be converted shall give written notice to the Corporation at its principal office that such holder elects to convert such shares of Series C-2 Preferred Stock or a specified portion thereof into shares of Common Stock as set forth in such notice (the “Conversion Notice”, and such date of delivery of the Conversion Notice to the Corporation, the “Conversion Notice Delivery Date”). Within two business days following the Conversion Notice Delivery Date, the Corporation shall issue and deliver a certificate or certificates representing the number of shares of Common Stock determined pursuant to this Section 3 (the “Share Delivery Date”). In case of conversion under this Section 3 of only a part of the shares of Series C-2 Preferred Stock represented by a certificate surrendered to the Corporation, the Corporation upon the request of a holder shall issue and deliver to the holder or its designee a new certificate for the number of shares of Series C-2 Preferred Stock which have not been converted, upon receipt of the original certificate or certificates representing shares of Series C-2 Preferred Stock so converted. Until such time as the certificate or certificates representing shares of Series C-2 Preferred Stock which have been converted are surrendered to the Corporation and a certificate or certificates representing the Common Stock into which such shares of Series C-2 Preferred Stock have been converted have been issued and delivered, the certificate or certificates representing the shares of Series C-2 Preferred Stock which have been converted shall represent the shares of Common Stock into which such shares of Series C-2 Preferred Stock have been converted. The Corporation shall pay all documentary, stamp or similar issue or transfer tax due on the issue of shares of Common Stock issuable upon conversion of the Series C-2 Preferred Stock.

 

(i) Buy-In. If, by the Share Delivery Date, the Corporation fails for any reason to deliver the shares of Common Stock issuable upon conversion of the Series C-2 Preferred Stock, as set forth in the Conversion Notice, and after such Share Delivery Date, the converting holder purchases, in an arm’s length open market transaction or otherwise, shares of Common Stock (the “Covering Shares”) in order to make delivery in satisfaction of a sale of Common Stock by the converting holder (the “Sold Shares”), which delivery such converting holder anticipated to make using the shares to be issued upon such conversion (a “Buy-In”), the converting holder shall have the right to require the Corporation to pay to the converting holder the Buy-In Adjustment Amount. The Corporation shall pay the Buy-In Adjustment Amount to the converting holder in immediately available funds immediately upon demand by the converting holder. For purposes of this Certificate of Designation, the term “Buy-In Adjustment Amount” means the amount equal to the excess, if any, of (i) the converting holder’s total purchase price (including brokerage commissions, if any) for the Covering Shares associated with a Buy-In, over (ii) the net proceeds (after brokerage commissions, if any) received by the converting holder from the sale of the Sold Shares. By way of illustration and not in limitation of the foregoing, if the converting holder purchases shares of Common Stock having a total purchase price (including brokerage commissions) of $11,000 to cover a Buy-In, with respect to shares of Common Stock it sold for net proceeds of $10,000, the Buy-In Adjustment Amount which the Corporation will be required to pay to the converting holder will be $1,000.

 

 

 

 

3.3 Other Provisions.

 

(i) Reservation of Common Stock. The Corporation shall at all times reserve from its authorized Common Stock a sufficient number of shares to provide for conversion of all Series C-2 Preferred Stock from time to time outstanding.

 

(ii) Record Holders. The Corporation and its transfer agent, if any, for the Series C-2 Preferred Stock may deem and treat the record holder of any shares of Series C-2 Preferred Stock as reflected on the books and records of the Corporation as the sole true and lawful owner thereof for all purposes, and neither the Corporation nor any such transfer agent shall be affected by any notice to the contrary.

 

(iii) Restriction and Limitations. Except as expressly provided herein or as required by law so long as any shares of Series C-2 Preferred Stock remain outstanding, the Corporation shall not, without the vote or written consent of the holders of at least a majority of the then outstanding shares of the Series C-2 Preferred Stock, take any action to modify the terms of the shares of Series C-2 Preferred stock or take any other action, including the creation of a new class or series of stock in the Corporation or the modification of the terms of any existing series or class of stock in the Corporation, which would, in the reasonable opinion of the holder, adversely affect any of the preferences, limitations or relative rights of the Series C-2 Preferred Stock.

 

(iv) Further Limitation. In no event shall the Series C-2 Preferred Stock be convertible until on or after November 1, 2022.

 

4. Certain Adjustments.

 

4.1 Stock Dividends and Stock Splits. If the Corporation, at any time while the Series C-2 Preferred Stock is outstanding: (A) shall pay a stock dividend or otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation pursuant to the Series C-2 Preferred Stock), (B) subdivide outstanding shares of Common Stock into a larger number of shares, (C) combine (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (D) issue by reclassification of shares of the Common Stock any shares of capital stock of the Corporation, the Conversion Rate in effect immediately prior to any such event shall be proportionately adjusted, and each share of Series C-2 Preferred Stock shall receive such consideration as if such number of shares of Series C-2 Preferred Stock had been, immediately prior to such foregoing dividend, distribution, subdivision, combination or reclassification, the holder of the number of shares of Common Stock into which it could convert at such time. Any adjustment made pursuant to this Section shall become effective immediately upon the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately upon the effective date in the case of a subdivision, combination or re-classification.

 

 
 

 

IN WITNESS WHEREOF, the undersigned has executed this Certificate this 21 day of October 2021.

 

  By: /S/ Leslie Buttorff
  Name: Leslie Buttorff
  Title: Chief Executive Officer